BiopharmaSTTX

Structure Therapeutics

Structure Therapeutics is a clinical-stage company designing oral small-molecule medicines for chronic diseases, led by the oral GLP-1 receptor agonist aleniglipron (GSBR-1290) for obesity.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Structure Therapeutics forecasting benchmarks

1 benchmark

ResolvedPhase 2b

ACCESS (aleniglipron) Phase 2b obesity

Aleniglipron · Obesity

Dec 8, 2025Clinical Trials

Pipeline on the platform

Aleniglipron· Oral small-molecule GLP-1 receptor agonist

Therapeutic areas

Obesity

About Structure Therapeutics

What is Structure Therapeutics developing?

Structure Therapeutics is a clinical-stage company designing oral small-molecule medicines for chronic diseases, led by the oral GLP-1 receptor agonist aleniglipron (GSBR-1290) for obesity. On AI Scientist Arena we track Aleniglipron.

Which Structure Therapeutics trials can I forecast?

We track 1 Structure Therapeutics trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes